Tag: Experian
-
Acute Hepatic and Renal Toxicity Associated with “Deferasirox” Treatment and the Impact of Genetic Factors in a Child with Major Beta Thalassemia
Introduction: The use of iron-chelating drug therapies is a vital component in managing patients who rely on blood transfusions, as these medications help prevent iron accumulation in vital organs and mitigate risks associated with iron overload. In this context, the drug “Deferasirox” (DFX) stands out as a commonly used option, but it has been associated…